Table 1.

Sources and data cut-offs used in primary and additional ITCs

Outcome	COMBI-v		coBRIM
	Data cut-off	Data source	Data cut-off	Data source
Efficacy outcomes
OS	Primary Analysis —March 2015 Additional analysis (without crossover)—April 2014 Additional analysis (LDH subgroups)—March 2015	Robert 2015b [29] Robert 2015a [27] Novartis Pharmaceuticals Corporation, unpublished observations	August 2015	Atkinson 2015 [30]
PFS	Primary analysis—March 2015	Robert 2015b [29]	January 2015	Larkin 2015c [32]
	Additional analysis LDH subgroups—April 2014	Novartis Pharmaceuticals Corporation, unpublished observations
ORR	April 2014	Robert 2015a [27]	January 2015	Larkin 2015c [32]
General adverse events
Any AE, any SAE, discontinuation due to AE, AE leading to death, any grade ≥3 AE	March 2015	Robert 2015b [29] and Novartis Pharmaceuticals Corporation, unpublished observations	September 2014	EMA label [33, 34]
Any treatment-related AE, any dose interruptions/modifications	April 2014	Robert 2015a [27]
Specific adverse events
All specific adverse events except those highlighted in the row below	March 2015	Robert 2015b [29] and Novartis Pharmaceuticals Corporation, unpublished observations	September 2014	EMA label
Keratocanthoma			May 2014	Larkin 2014 [21]
CuSCC—all grades	April 2014
Chills—all grades grade 3 to 5: alopecia, nausea, pyrexia, vomiting	March 2015		May 2014	EMA label

AE Adverse event, CuSS cutaneous squamous cell carcinoma, D + T dabrafenib plus trametinib, ECOG Eastern Cooperative Oncology Group, EMA European Medicines Agency, ITC Indirect treatment comparison, LDH lactate dehydrogenase, OS Overall survival, ORR Overall response rate, PFS Progression-free survival, SAE Severe adverse event, V vemurafenib, V + C vemurafenib plus cobimetinib